Skip to content

The efficacy of nalgesic (curcumin) in the treatment of pain in patients with osteoarthritis of the thumb

The efficacy of nalgesic (curcumin) in the treatment of pain in patients with osteoarthritis of the thumb

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12609000088246
Enrollment
10
Registered
2009-02-10
Start date
2009-01-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Osteoarthritis (OA) is a significant health issue and the burden of disease represented by OA is likely to escalate with the aging of the population OA of the hand is a common form of OA but has received much less research attention than OA of the hip or knee. While various treatments exist for OA, interest is increasing in those provided by naturally occurring compounds. These compounds, while safe, are often largely untested with respect to the claims made about their efficacy in the market place. We will examine whether curcumin (a derivative of tumeric) can provide pain relief and increased mobility of the thumb joint.

Interventions

We aim to recruit 10 volunteers who have the clinical diagnosis of (OsteoArthritis)OA of the thumb joint to enter a double blinded, placebo controlled study of Curcumin (Nalgesic) with three (single dose) oral administration (tablet) conditions (placebo, normal dose - 1200mg, and double dose 2400mg). This is a cross-over trial. All participants receive all the interventions in different sequences during the study. They act as their own control. There is a full 7 day period between treatments to

We aim to recruit 10 volunteers who have the clinical diagnosis of (OsteoArthritis)OA of the thumb joint to enter a double blinded, placebo controlled study of Curcumin (Nalgesic) with three (single dose) oral administration (tablet) conditions (placebo, normal dose - 1200mg, and double dose 2400mg). This is a cross-over trial. All participants receive all the interventions in different sequences during the study. They act as their own control. There is a full 7 day period between treatments to ensure washout of the trial drug. The trial will be conducted over three consecutive week-ends (Saturdays).

Sponsors

Deakin University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Diagnosis of OA of the thumb by a rheumatologist (Dr Daniel Lewis).

Exclusion criteria

Under 18 years of age Current anticoagulant therapy e.g. warfarin Current treatment for colorectal cancer Patients with gallstones Women pregnant, planning to become pregnant or currently breastfeeding

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026